Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

This cannibalization of existing products should be good for Vertex ... I don't think that's the case whatsoever with Vertex Pharmaceuticals. This big biotech stock should easily generate ...

Vertex Pharmaceuticals' (NASDAQ ... Vertex noted that illegal copycat versions of its products in the country are negatively impacting sales. However, the company believes the problem is isolated ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart ... We continue to reach more patients with more products and delivered $2.77 billion in revenue ...

CEO Reshma Kewalramani highlighted the company’s strong performance in Q1 2025, with $2.77 billion in revenue, representing a 3% year-over-year increase. Growth was driven by expanding patient reach ...

Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2025 ... We continue to reach more patients with more products and delivered $2.77 billion in revenue in the first quarter ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle ... We continue to reach more patients with more products and delivered $2.77 billion in ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company ...

Vertex Pharmaceuticals Incorporated VRTX reported ... VRTX’s total revenues comprised cystic fibrosis (“CF”) and other products revenues, as well as other collaboration revenues.